Schizophrenia Market Share, Size, Growth, Analysis, Overview and Pipeline Review, H1 2016



Schizophrenia Market Share, Size, Growth, Analysis, Overview and Pipeline Review, H1 2016
Schizophrenia Market Share, Size, Overview and Pipeline
Review, H1 2016 by Radiant Insights
Global Markets Direct's, 'Schizophrenia - Pipeline Review, H1 2016', provides an overview of the Schizophrenia
pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Schizophrenia,
complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases. Additionally, the report provides
an overview of key players involved in therapeutic development for Schizophrenia and features dormant and
discontinued projects.
Get Full Details On:
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Schizophrenia
- The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes
based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description,
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects
- The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Schizophrenia
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of
Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove
them from pipeline
Table of Contents
Table of Contents 2
Introduction 6
Schizophrenia Overview 7
Therapeutics Development 8
Schizophrenia - Therapeutics under Development by Companies 10
Schizophrenia - Therapeutics under Investigation by Universities/Institutes 17
Schizophrenia - Pipeline Products Glance 18
Schizophrenia - Products under Development by Companies 22
Schizophrenia - Products under Investigation by Universities/Institutes 32
Schizophrenia - Companies Involved in Therapeutics Development 33
Schizophrenia - Therapeutics Assessment 112
Drug Profiles 129
Schizophrenia - Recent Pipeline Updates 329
Schizophrenia - Dormant Projects 387
Schizophrenia - Discontinued Products 402
Schizophrenia - Product Development Milestones 408
Appendix 416
Get Full Details On:
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure market research reports, helping them
in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries
and a host of micro markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: [email protected]
Visit our Blog:

Similar documents

Schizophrenia Treatment Market to Make Great Impact In Near Future by 2026

Schizophrenia Treatment Market to Make Great Impact In Near Future by 2026 Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and restore one’s ability to function and enjoy a meaningful life. The signs of schizophrenia are different for everyone. Symptoms may develop slowly over months or years, or may appear very abruptly. The disease may come and go in relapse and remission. Hence, recovery from schizophrenia is a lifelong process. SchizophreniaTreatment Market: Drivers and Restraints

More information